Targeting the MAPK–RAS–RAF signaling pathway in cancer therapy
Top Cited Papers
- 12 January 2012
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 16 (1), 103-119
- https://doi.org/10.1517/14728222.2011.645805
Abstract
Introduction: The MAPK pathway comprises several key signaling components and phosphorylation events that play a role in tumorigenesis. These activated kinases transmit extracellular signals that r...Keywords
This publication has 102 references indexed in Scilit:
- Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3KCancer Cell, 2010
- Ras superfamily GEFs and GAPs: validated and tractable targets for cancer therapy?Nature Reviews Cancer, 2010
- Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanomaNature, 2010
- Targeting the MAPK pathway in melanoma: Why some approaches succeed and other failBiochemical Pharmacology, 2010
- RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAFNature, 2010
- Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAFCell, 2010
- Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistanceBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2006
- BRAF mutation predicts sensitivity to MEK inhibitionNature, 2005
- The RAF proteins take centre stageNature Reviews Molecular Cell Biology, 2004
- Mutations of the BRAF gene in human cancerNature, 2002